STEMINOV
StemInov is a biotechnology company that focuses on the development of stem cell therapies for inflammatory diseases. The company's primary focus is on critical care, specifically septic shock and Acute Respiratory Distress Syndrome (ARDS). StemInov's approach is based on robust preclinical data and widely accepted safety measures. The company is developing an off-the-shelf and allogenic cell therapy. StemInov is also working on a drug-based therapy using mesenchymatous stem cells from Wharton's jelly (WJ-MSC).
STEMINOV
Social Links:
Industry:
Biotechnology Clinical Trials Life Science STEM Education
Address:
Vandoeuvre-lès-nancy, Lorraine, France
Country:
France
Website Url:
http://www.steminov.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Euro Google Google Cloud Wix
Similar Organizations
Medrego
Medrego develops stem cell treatments, gene therapy, and custom solutions for animals.
OmiCure
OmiCure helps clinicians choose therapy and diet for cancer patients.
OneChain Immunotherapeutics
OCI develops therapies for leukaemia based on CAR–T.
Preome
Preome is the Predictive Super Biomarker company, transforming clinical success.
Probiomics Care
Probiomics Care develops basic and clinical research models for chronic and complex diseases.
Reflection Therapeutics
Reflection Therapeutics is developing cell therapy technology against neuroinflammation across the board.
Sesmos
Sesmos is develops drug candidates for oncology and inflammatory diseases.
Current Employees Featured
Founder
Investors List
Incubateur Lorrain
Incubateur Lorrain investment in Non Equity Assistance - StemInov
Official Site Inspections
http://www.steminov.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "StemInov"
Cell Therapy | Steminov
Lead to the patent operated by StemInov. 70 Publications in ATMP over the last 12 yrs. Danièle BENSOUSSAN . CSO & Co-founder. Eric is a serial entrepreneur who combines strong strategic, technological and managerial experience with proven track record of deal-making and fund …See details»
StemInov - Crunchbase Company Profile & Funding
StemInov is a biotechnology company that focuses on the development of stem cell therapies for inflammatory diseases. The company's primary focus is on critical care, specifically septic shock and Acute Respiratory Distress …See details»
About Us - Steminov
StemInov is a clinical stage company, spin-off from Nancy’s Teaching Hospital and Lorraine Region’s Uni. The company develops an off-the-shelf, allogenic stem cell therapy treatment, in the field of inflammatory pathologies, with a …See details»
Investors - Steminov
Based on a robust preclinical data and on largely admitted safety, StemInov is preparing a phase I/II efficacity trial on pneumonia patients, developing septic shock or ARDS. Septic shock is a medical emergency: 50% of mortality rate …See details»
StemInov Company Profile 2025: Valuation, Funding & Investors
StemInov General Information Description. Developer of biomedicine and drugs intended to treat people with septic shock. The company is engaged in the clinical development of biomedicine using mesenchymal stem cells from the umbilical cord, enabling the medical community to …See details»
STEMINOV Company Profile | VANDOEUVRE-LES-NANCY ... - Dun …
Steminov. d&b business directory home / business directory / professional, scientific, and technical services / architectural, engineering, and related services / france / grand est / vandoeuvre-les-nancy / steminov; steminov. get a d&b hoovers free trial. overviewSee details»
StemInov - Funding, Financials, Valuation & Investors - Crunchbase
Jan 15, 2019 StemInov develops stem cell therapies for inflammatory diseases, focusing on septic shock and ARDS. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much funding has this organization raised over time? Show . Announced Date . …See details»
StemInov - euroquity.com
About your organization •StemInov is developping WhartSep® a stem cell based therapy which has a unique, 3 in 1, adaptive mode of action to treat septic shock & ARDS (patented): - Ability to migrate to damaged organs and tropism for lungs - Direct and indirect antibacterial effect - Pro …See details»
STEMINOV (VANDOEUVRE-LES-NANCY) Chiffre d'affaires, résultat, …
STEMINOV, société par actions simplifiée, au capital social de 28000,00 EURO, dont le siège social est situé au 2 AV DE LA FORET DE HAYE, 54500 VANDOEUVRE-LES-NANCY, immatriculée au Registre du Commerce et des Sociétés de Nancy sous le numéro 845327352 …See details»
StemInov - Tech Stack, Apps, Patents & Trademarks - Crunchbase
StemInov develops stem cell therapies for inflammatory diseases, focusing on septic shock and ARDS.See details»
StemInov - LinkedIn
⚗ À #Nancy, StemInov reçoit 5,2 M€ de financement public pour avancer sur la production industrielle de cellules souches du cordon ombilical. La start-up, en partenariat avec le CHRU de ...See details»
StemInov - Products, Competitors, Financials, Employees, …
La start-up StemInov et le CHRU de Nancy vont développer une plateforme de production de cellules souches. Jun 26, 2024. 1 min de lecture Le consortium Sesame, réunissant la start-up nancéienne StemInov, chef de file du projet , et le Centre hospitalier régional universitaire de …See details»
StemInov Will Bioproduct the First Cell Therapy Drug to Treat ...
Jun 11, 2023 NANCY-STRASBOURG, France –StemInov, a biotechnology company developing an innovative biomedicine based on stem cells from umbilical cords to treat inflammatory diseases, septic shock and acute respiratory distress syndrome (ARDS), will bioproduct the …See details»
StemInov - Contacts, Employees, Board Members, Advisors
StemInov develops stem cell therapies for inflammatory diseases, focusing on septic shock and ARDS.See details»
News - Steminov
StemInov will be glad to meet you at its booth in the Grand Est Region corner at Biofit! 09/2022. StemInov wins Be a Boss award 2022. After winning the regional selection of the Grand Est on September 7th, Julie Hutin, StemInov, won on the 22nd of september the national final in Paris!See details»
StemInov Will Bioproduct the First Cell Therapy Drug to Treat ...
Jun 5, 2023 "StemInov will be present at the Bio International Convention in Boston from 5 to 8 June 2023 on the French Pavillon as we are in the process of preparing our next fundraising which will allow us ...See details»
StemInov - BioFIT Exhibitor
StemInov is a clinical stage spin-off from CHRU of Nancy and University of Lorraine that develops an off-the-shelf and allogenic cell therapy treatment in the field of inflammatory pathologies with a focus on critical care. More than a new product, our proprietary Stem cells from the Wharton …See details»
Clinical Development - StemInov
Based on robust preclinical data and on largely admitted safety of WhartSep, StemInov is preparing a phase Ib trial in severe pneumonia patients admitted in ICU. Preclinical Studies. IN MICE. WJ-MSC HAVE SHOWN GREAT SAFETY & EFFICACY IN SEPTIC SHOCK ...See details»
Mechanism Of Action - Steminov
WJ-MSC Mode of Action & unique properties. MSCs have the ability to migrate by themselves to damaged sites and to respond appropriately to the environment in which they are placed, and to acquire an adaptive pro-inflammatory (called MSC1) or anti-inflammatory (called MSC2) …See details»
StemInov Will Bioproduct the First Cell Therapy Drug to Treat ...
Jun 5, 2023 NANCY-STRASBOURG, France--(BUSINESS WIRE)-- StemInov, a biotechnology company developing an innovative biomedicine based on stem cells from umbilical cords to treat inflammatory diseases, septic shock and acute respiratory distress syndrome (ARDS), will …See details»